International Journal of Trichology International Journal of Trichology
 Print this page Email this page Small font sizeDefault font sizeIncrease font size
  Home | About IJT | Editorial board | Search | Ahead of print | Current Issue | Archives | Instructions | Online submission | Subscribe | Advertise | Contact us | Reader Login  
Export selected to
Reference Manager
Medlars Format
RefWorks Format
BibTex Format
  Access statistics : Table of Contents
   2018| November-December  | Volume 10 | Issue 6  
    Online since February 1, 2019

  Archives   Previous Issue   Next Issue   Most popular articles   Most cited articles
Hide all abstracts  Show selected abstracts  Export selected to
  Viewed PDF Cited
A comment on the post-finasteride syndrome
Hudson Dutra Rezende, Maria Fernanda Reis Gavazzoni Dias, Ralph Michel Trueb
November-December 2018, 10(6):255-261
DOI:10.4103/ijt.ijt_61_18  PMID:30783332
The post-Finasteride syndrome (PFS) has been claimed to occur in men who have taken oral finasteride to treat hair loss or benign prostatic hyperplasia. While the incidence of persistent sexual, mental, and physical side effects despite quitting finasteride is unknown, and the condition is not recognized by the scientific community, individuals who suffer from PFS do present with very distinctive and homogenous symptoms. The concept has emerged from reports of nondermatologists, neuroendocrinological research, case reports, and uncontrolled studies. These have been scrutinized by hair experts who found that persistent sexual side effects were only documented in low-quality studies with a strong bias selection and a significant nocebo effect. Others totally dispute the credibility of the PFS. In any case, the PFS is a problem that has to be dealt with. Low-quality studies neither confirm nor refute the condition as a valid nosologic entity. Therefore, it is as inappropriate to dismiss the condition, as it would be to demonize finasteride for the treatment of male pattern hair loss. Whether the PFS represents a nocebo reaction or a real drug adverse event is irrelevant, while the best way to alleviate the emotional distress related to hair loss is to effectively treat the condition causing the problem. It is not sufficient to only discuss the plausibility of the PFS. There is a need for practical recommendations to include such important issues as patient selection and risk assessment, appropriate patient information, how to react in case of drug-related adverse events, issues of fertility and malignancy, management of the PFS, and alternatives, specifically the use of topical finasteride. It is the aim of this commentary to provide the respective information.
  28,249 91 10
Scalp condition impacts hair growth and retention via oxidative stress
Ralph M Trueb, Jim P Henry, Mike G Davis, Jim R Schwartz
November-December 2018, 10(6):262-270
DOI:10.4103/ijt.ijt_57_18  PMID:30783333
Conventionally, the medical focus has been either on hair loss or the condition of the scalp in terms of specific dermatological diseases. Indeed, the proximate structural arrangement of the scalp and hair leads to an interdependent relationship between the two. While protective benefits of the hair to the scalp are obvious, the role of the scalp as an incubatory environment for the preemergent hair fiber has largely been ignored. In fact, there is a wealth of observational data on specific dermatological conditions of the scalp providing evidence for the role of the scalp condition in supporting the production of healthy hair. Oxidative stress, the inability of the body to sufficiently counteract the sources of oxidation, is prevalent in many skin conditions, including normal skin aging. On the scalp, the hair appears to be impacted prior to emergence, and oxidative stress appears to play a role in premature hair loss. The scalp commensal organism, Malassezia, has been recognized to be a source of oxidative damage. Therefore, hair care products, specifically shampoos, with active Malassezia inhibitory agents, such as zinc pyrithione, tend to reduce premature hair loss, besides the known benefits in treating specific dermatologic scalp pathologies, and therefore should represent an integral part of every treatment regimen for hair loss, even in individuals not showing symptoms of scalp pathologies.
  26,831 182 19
A comment on the science of hair aging
Ralph M Trueb, Hudson Dutra Rezende, Maria Fernanda Reis Gavazzoni Dias
November-December 2018, 10(6):245-254
DOI:10.4103/ijt.ijt_56_18  PMID:30783331
In contrast to the skin, aging of the hair has seemingly only recently found the attention of dermatological meetings, mainly promoted by the cosmetic industry for marketing purposes. In fact, basic scientists interested in the biology of hair growth and pigmentation have for some time already exposed the hair follicle as a highly accessible model with unique opportunities for the study of age-related effects. As a result, the science of hair aging focuses on two main streams of interest: the esthetic problem of aging hair and its management, in terms of age-related effects on hair color, quantity, and quality; and the biological problem of aging hair, in terms of microscopic, biochemical, and molecular changes underlying the aging process. Ultimately, the aim of hair anti-aging is to delay, lessen, or reverse the effects of aging on hair. According to the complex nature of the aging process, the treatment for lifetime scalp and hair health has to be holistic to include the multitude of contributing factors in a polyhedral and patient-specific manner. It comprises both medical treatments and hair cosmetics. Accordingly, the discovery of pharmacological targets and the development of safe and effective drugs for treatment of hair loss indicate strategies of the drug industry for maintenance of hair growth and quantity, while the hair care industry has become capable of delivering active compounds directed toward meeting the consumer demand for maintenance of hair cosmesis and quality. “Where there's life, there's hope” (Ecclesiastes 9:3-5).
  7,731 78 9
The impact of alopecia areata on sexual quality of life
Sara J Li, Kathie P Huang, Cara Joyce, Arash Mostaghimi
November-December 2018, 10(6):271-274
DOI:10.4103/ijt.ijt_93_18  PMID:30783334
Background: Alopecia areata (AA) is an autoimmune disease characterized by patches of hair loss that can cause decreased quality of life. This study evaluates the sexual quality of life for patients with AA. Methods: We surveyed patients in the National Alopecia Areata Foundation patient registry using an online version of the validated Sexual Quality of Life for Females (SQOL-F) and Sexual Quality of Life for Males (SQOL-M) questionnaires. Main Outcome Measures: Patient sexual quality of life was measured using the SQOL-F and SQOL-M instruments. Results: Eighty-one participants with AA (64 females and 17 males) completed the surveys. The mean age was 39.7 ± 13.8 years for women and 37.4 ± 9.9 years for men. Women had a decreased sexual quality of life with mean SQOL-F score of 51.3 ± 22.9. Men had a decreased sexual quality of life with mean SQOL-M score of 62.7 ± 33.9 (higher scores indicate greater sexual quality of life). No statistical difference was found between these two cohorts (P = 0.12). In discussing negative aspects of their sexuality, women strongly identified with emotional statements such as “I feel embarrassed” (n = 48, 75.0%) while men strongly identified with emotional statements such as “I feel anxious” (n = 7, 46.7%). Both cohorts strongly identified with “I feel like I have lost something” (n = 48, 76.2% and n = 7, 43.8%, respectively). Conclusions: This study demonstrates that AA has a negative impact on the patient's sexual quality of life.
  6,121 33 9
Suspected herpes zoster-associated encephalitis during treatment with oral tofacitinib in alopecia universalis
Anna-Marie Hosking, Margit Juhász, Natasha Atanaskova Mesinkovska
November-December 2018, 10(6):286-288
DOI:10.4103/ijt.ijt_87_18  PMID:30783338
Systemic administration of Janus kinase inhibitors (JAKis) is associated with adverse events, including serious infections, malignancy, and herpes zoster (HZ). Herein, we report a case of a 17-year-old male with alopecia universalis who developed suspected HZ-associated encephalitis (HZAE) during treatment with oral tofacitinib. Oral tofacitinib was immediately discontinued, and the patient was started on antiviral treatment. We present this case to highlight a serious complication that can arise with oral JAKi therapy. Physicians should have a high index of clinical suspicion for HZAE in any patient presenting with a vesicular rash and concomitant neurologic impairments while systemically immunosuppressed.
  3,667 23 1
New-onset androgenic alopecia following human chorionic gonadotropic diet and testosterone pellet implantation
Jacob Griggs, Hind Almohanna, Azhar Ahmed, Antonella Tosti
November-December 2018, 10(6):284-285
DOI:10.4103/ijt.ijt_75_18  PMID:30783337
A diet involving human chorionic gonadotropic (hCG) injections combined with extreme caloric restriction is sometimes undertaken by people desiring rapid weight loss. We report a patient with new-onset androgenic alopecia following hCG diet combined with the implantation of testosterone pellets.
  3,657 22 1
Plucking, picking, and pulling: The hair-raising history of trichotillomania
Rachel LV Waas, Paul Devakar Yesudian
November-December 2018, 10(6):289-290
DOI:10.4103/ijt.ijt_69_18  PMID:30783339
  3,492 23 -
Relationship between trace elements and premature hair graying
Alshimaa M El-Sheikh, Nashwa N Elfar, Heba A Mourad, El-Sayed S Hewedy
November-December 2018, 10(6):278-283
Context: Hair is said to gray prematurely when a minimum of five gray hairs occurs before the age of 20 in fair skinned, 25 in Asians, and 30 in Africans. It may be genetically associated with autoimmune syndromes or certain environmental factors. Aims: The aim of this study was to evaluate the serum level of iron, copper, and calcium and to assess their role in premature hair graying. Subjects and Methods: This study was carried out on 60 patients with premature hair graying (PHG) and 30 age- and sex-matched healthy individuals served as a control group. The severity of PHG was assessed by the hair whitening scoring system. Serum iron, copper, and calcium concentrations were measured using Beckman Coulter instrument and spectrophotometric method. Results: There was a reduction in serum levels of iron, copper, and calcium in patients with PHG in comparison with controls. There was a statistically negative significant correlation between the severity of PHG and serum iron and calcium levels. There was a negative nonsignificant correlation between body mass index and serum iron, copper, and calcium levels. Conclusions: Serum iron, copper, and calcium levels were reduced in association with PHG and correlated with its severity. Premature graying may be an indicator that hair is not getting enough nutrients and minerals, and supplementation with these trace elements might reverse and is expected to prevent progression of canities; however, further studies are needed to find the underlying mechanism of this relationship.
  2,997 53 4
Nuchal nevus flammeus and alopecia areata: When size matters
Andrea Combalia, Lizet Rojano-Fritz, Sebastian Podlipnik, Juan Ferrando
November-December 2018, 10(6):275-277
DOI:10.4103/ijt.ijt_82_18  PMID:30783335
Introduction: Alopecia areata (AA) is a high-prevalence immuno-mediated hair loss disorder. Extra follicular affections, including nail and ocular abnormalities, are classically related to a worse prognosis of the disease, and previous studies have suggested that the presence of a persistent nuchal nevus flammeus (NNF) also indicates a greater severity and duration of the disease. The association between AA and persistent NNF was first described by Hatzis et al in 1988, who demonstrated that the relation was statistically evident and not due to a simple observer bias. Objectives: To determine and compare the presence/absence and size of the NNF in 80 individuals (40 patients diagnosed with AA and 40 controls). Results: We found a statistically significant association not only between AA and the presence of NNF, but also with its size. Moreover, we found that the size of the NNF was also associated with the severity of AA. Conclusion: The size of the NNF in AA patients might be a useful marker of widespread and chronic disease.
  2,846 23 -
Congenital triangular alopecia: A brief report
Yu-Lei Zhao, Ru-Zhi Zhang
November-December 2018, 10(6):290-291
DOI:10.4103/ijt.ijt_68_18  PMID:30783340
  2,779 26 3
A case of idiopathic hemihypertrophy with hemihypertrichosis
Jung Eun Seol, So Hee Park, Jong Uk Kim, Gyeong Je Cho, Seung Hyun Moon, Hyojin Kim
November-December 2018, 10(6):292-293
DOI:10.4103/ijt.ijt_55_18  PMID:30783341
  2,675 18 1